Agenus (AGEN) Stock Forecast & Price Target

Agenus is expected to generate significant revenue growth in the coming years thanks to its pipeline of immunotherapy treatments, with revenue projections of $140.3 million for 2026. However, the company also saw a 24% increase in operating expenses in the second quarter of 2026, likely due to costs associated with its discontinued Phase 3 BATTMAN trial. The recent shift in strategy to focus on the neoadjuvant setting and the private placement of $85 million may result in short-term effects on the stock price, but the company's potential $255 million in additional funds from warrant exercise and strong financial position with $118 million in cash position for the third quarter of 2026 suggest long-term potential for Agenus.

Agenus is rated as a "Buy" with a $25 price target based on a discounted cash flow (DCF) analysis through 2040. While there may be short-term risks such as safety signals or lower-than-expected efficacy in clinical trials, the current valuation does not account for the potential value of the company's other pipeline assets or indications. However, risks to achieving the price target include potential safety signals, commercial competition, changes to France AAC and NPP programs, regulatory concerns, financing requirements, and intellectual property protection.